U.S. Capital Wealth Advisors LLC Raises Stock Holdings in Eli Lilly and Company (NYSE:LLY)

U.S. Capital Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 7.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,620 shares of the company’s stock after purchasing an additional 631 shares during the quarter. U.S. Capital Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $7,636,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. M&G Plc purchased a new position in shares of Eli Lilly and Company during the first quarter worth about $8,896,000. Virtu Financial LLC purchased a new position in shares of Eli Lilly and Company during the first quarter worth about $2,138,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Eli Lilly and Company by 19.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock worth $7,699,000 after purchasing an additional 1,620 shares in the last quarter. Mutual Advisors LLC grew its holdings in shares of Eli Lilly and Company by 404.8% during the first quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock worth $48,699,000 after purchasing an additional 50,197 shares in the last quarter. Finally, Private Advisor Group LLC lifted its position in Eli Lilly and Company by 0.6% in the 1st quarter. Private Advisor Group LLC now owns 76,282 shares of the company’s stock worth $59,345,000 after buying an additional 430 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on LLY shares. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday, September 16th. Truist Financial boosted their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Citigroup started coverage on Eli Lilly and Company in a research report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 target price for the company. Guggenheim boosted their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Finally, Berenberg Bank boosted their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,002.24.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $902.96 on Thursday. The company has a market cap of $858.18 billion, a PE ratio of 132.98, a P/E/G ratio of 2.79 and a beta of 0.42. The business has a 50 day moving average of $921.12 and a 200 day moving average of $860.74. Eli Lilly and Company has a 52 week low of $547.61 and a 52 week high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, equities research analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.